Results 111 to 120 of about 4,106,944 (201)

The TCR in CAR T cell therapy: use it or lose it? [PDF]

Cancer Gene Ther
Liseth O, Vile R.
europepmc   +1 more source

Highlights in IO: next-generation CAR-T therapy for glioblastoma. [PDF]

J Immunother Cancer
Yamaguchi J, Okada H.
europepmc   +1 more source

LRRC15-CAR T Cells for the Treatment of Osteosarcoma. [PDF]

Clin Cancer Res
O'Reilly C, Tuladhar S, Nguyen P, Sheppard H, Koo SC, Chockley P, Houke H, Santiago T, Tian L, Jeschke J, Beckett AN, Chabot A, Yustein J, Krenciute G, Talbot LJ, Gottschalk S, DeRenzo C.   +16 more
europepmc   +1 more source

CAR-T cells in solid tumors: engineering, biomarkers, translational pathways and the road ahead. [PDF]

Front Immunol
Al Shaer NSH, Masoud I, Tleyjeh A, Al-Attas AA, Al-Attas MA, Khan MI, Yaqinuddin A.   +6 more
europepmc   +1 more source

Cortisol-resistant CAR-NK cells overcome steroid-induced immunosuppression in lung cancer. [PDF]

Signal Transduct Target Ther
Chakraborty S, Pramanik J, Alviter-Raymundo G, Ward CJ, Shaji SK, Yamashita-Kanemaru Y, Ali FAZ, Banik D, Zhang Z, Veiga-Villauriz C, Homer NZM, Simpson J, Laforest S, Tong S, Zhao Q, Roy J, Iqbal M, Morris AC, Chapman MA, Roychoudhuri R, Hussein H, Klenerman D, Saeb-Parsy K, Mahata B.   +23 more
europepmc   +1 more source

Combining Small-Molecular Compounds With CAR T-Cell Therapy: Novel Strategies for Enhanced Cancer Immunotherapy. [PDF]

Cancer Innov
Yi R, Zhang Z, Yang Y, Zhu H.
europepmc   +1 more source

Data-informed optimization of CAR T-cell therapy long-term follow-up. [PDF]

J Immunother Cancer
Foss-Campbell B, Myers N, Awasthi R, Bechtle D, Boerstoel Streefland M, Corbett W, Dewees B, Eastwood G, Jadlowsky J, Martin LJ, Langeberg W, Lee E, Marshall A, Nichols G, Shapiro J, Shiu L, Stewart M, Tschernia NP, Willert J, Xu H, June CH.   +20 more
europepmc   +1 more source

Potential of small-molecule targeted drugs in combination with CAR-T cell therapy for hematologic lymphomas. [PDF]

Front Immunol
Tang W, Yu S.
europepmc   +1 more source

RASA2 deletion rescues immune synapse dysfunction, enhancing CAR T cell efficacy against DMGs. [PDF]

J Immunother Cancer
Ibanez-Vega J, Teis R, Ocasio JK, Chockley P, Ansari A, Allo Anido A, Mehta S, Meehl M, Prinzing B, Ward M, Odde D, Baker S, Krenciute G.   +12 more
europepmc   +1 more source